Concepedia

Author

Jason M. Melear

Texas Oncology

Also Known As

J. Burke, J. M. Melear, J. Melear, J.M. Melear, Jason M Melear, Jason M. Melear, Jason Melear, Lang, Frederick F., Ramakrishna, Rohan

80

Publications

1.1K

Citations

13

H-Index

35

Concepts

All Affiliations

Texas OncologyRocky Mountain Cancer CentersWillamette Valley Cancer Institute and Research CenterCornell UniversityOncology Hematology Care
JM

About

Jason M. Melear is an author at Texas Oncology specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

350

2

Health Sciences

2

2

47

3

Cell Biology

2

2

22

4

Engineering

1

1

11

5

Hepatology

1

1

11

Jason M. Melear

×

21

Publications

939

Citations

13

H-Index

YearCitations

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold,

The Lancet Haematology

2019

249

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri, Vikas Patil, Leeor Yefet,

Nature Medicine

2023

232

Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1

Jason M. Melear, Robert M. Goldstein, Marlon F. Levy,

Transplantation

2002

86

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: <scp>LYRA</scp> study

Habte Yimer, Jason M. Melear, Edward A. Faber,

British Journal of Haematology

2019

66

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

R. Charles Coombes, Sacha J. Howell, Simon Lord,

Nature Communications

2023

54

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Ruth Plummer, Emma Dean, Hendrik‐Tobias Arkenau,

Lung Cancer

2021

33

LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Gelareh Zadeh, Mariza Daras, Timothy F. Cloughesy,

Neuro-Oncology

2020

26

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, Amrita Krishnan, Nina Shah,

Blood

2019

22

Phase IIIb randomized study of lenalidomide plus rituximab (R<sup>2</sup>) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).

David Andorsky, Abdulraheem Yacoub, Jason M. Melear,

Journal of Clinical Oncology

2017

21

MAGNIFY: Phase IIIb interim analysis of induction R<sup>2</sup> followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.

David Andorsky, Morton Coleman, Abdulraheem Yacoub,

Journal of Clinical Oncology

2019

17

Page 1